*All compounds discussed on this page are sold by BioPharma for in vitro research purposes only. They are not intended for human or veterinary use. This content is provided for informational purposes and does not constitute medical advice.*

When it comes to high-potency SARMs for results-driven research, RAD-140 stands at the top. Also known as testolone, RAD-140 is one of the most powerful selective androgen receptor modulators studied in modern performance research — and this RAD-140 research guide covers everything you need to understand its mechanism, research profile, and how it compares to other compounds in the space.

Whether you’re evaluating RAD-140 for muscle tissue research, neuroprotection studies, or as part of a broader SARMs research protocol, this guide provides the detailed, no-nonsense breakdown you need.

What Is RAD-140 (Testolone)?

RAD-140, commonly referred to as testolone, is a non-steroidal selective androgen receptor modulator developed for research applications focused on muscle wasting, neurodegeneration, and breast cancer. It was originally developed by Radius Health and has since become one of the most studied SARMs in the performance research community.

What sets RAD-140 apart:

  • High anabolic potency: RAD-140 demonstrates one of the highest anabolic-to-androgenic ratios among studied SARMs, with research models showing an anabolic effect comparable to testosterone at research-relevant concentrations
  • Tissue selectivity: Strong binding affinity in muscle and bone tissue with minimal activation in the prostate and sebaceous glands
  • Oral bioavailability: Non-steroidal structure allows for oral administration in research settings
  • Neuroprotective potential: Emerging research has examined RAD-140 for potential neuroprotective effects, a relatively unique research direction among SARMs

RAD-140 is not approved for human consumption and is sold by BioPharma exclusively for in vitro research purposes.

How RAD-140 Works: Mechanism of Action

Androgen Receptor Binding and Activation

RAD-140 binds directly to the androgen receptor (AR) with high affinity. Once bound, the RAD-140-AR complex undergoes a conformational change and translocates to the nucleus, where it modulates gene transcription in androgen-responsive tissues.

What makes RAD-140 selective is its tissue-specific co-regulator recruitment pattern:

  • In muscle tissue: The RAD-140-AR complex recruits co-activator proteins, promoting anabolic gene expression — increased protein synthesis, muscle cell proliferation, and nitrogen retention
  • In prostate and sebaceous glands: The same complex preferentially recruits co-repressor proteins, minimizing androgenic activation in these tissues

This selective co-regulator recruitment is the hallmark of SARM pharmacology, and RAD-140 executes it with exceptional potency and specificity.

Receptor Binding Affinity

In receptor binding assays, RAD-140 shows a binding affinity (Ki) approximately 5-8 times higher than many other SARMs studied under similar conditions. This translates to stronger anabolic signaling at lower concentrations in muscle tissue models — a key reason RAD-140 is considered one of the most potent SARMs available for research.

Neuroprotective Mechanism

One of RAD-140’s most interesting research directions involves neuroprotection. Preclinical studies have investigated whether RAD-140 can protect neurons through androgen receptor-mediated signaling in the brain. Proposed mechanisms include:

  • Activation of MAPK/ERK signaling pathways that promote cell survival
  • Reduction of oxidative stress markers in neuronal tissue
  • Induction of neurotrophic factors through AR activation in the hippocampus

This neuroprotective angle distinguishes RAD-140 from most other SARMs and opens research directions beyond traditional muscle and bone studies. For a broader overview of SARMs categories, see the SARMs research guide.

RAD-140 Research Applications

Muscle Tissue and Anabolic Research

The primary research focus for RAD-140 involves skeletal muscle tissue. In vitro and animal studies have documented:

  • Increased muscle fiber cross-sectional area
  • Enhanced myogenic differentiation in satellite cell models
  • Elevated protein synthesis rates in muscle tissue
  • Dose-dependent anabolic effects with a favorable therapeutic index in preclinical models

Compared to other SARMs, RAD-140 consistently ranks among the most potent in terms of anabolic output in muscle tissue assays. This has made it a reference compound in SARMs research — the benchmark against which newer compounds are measured.

Neuroprotection and Brain Health Research

RAD-140’s neuroprotective potential represents a compelling and distinct research direction. Studies in animal models of neurodegeneration have shown that RAD-140 can:

  • Reduce kainic acid-induced neuronal death in the hippocampus
  • Activate signaling pathways associated with cell survival (MAPK/ERK)
  • Decrease markers of oxidative stress and apoptosis in neuronal cultures

These findings suggest that androgen receptor modulation in the brain may have therapeutic potential, though all research remains preclinical and RAD-140 is not approved for any medical use.

Breast Cancer Research

An often-overlooked area of RAD-140 research involves its potential application in hormone-receptor-positive breast cancer models. Because RAD-140 competes with endogenous estrogens for receptor-related signaling pathways, researchers have examined whether AR agonism can suppress estrogen-driven tumor growth in certain breast cancer cell lines. Published preclinical data supports this avenue of investigation, though clinical validation is lacking.

Bone Density and Turnover Research

Like other SARMs, RAD-140 has been studied for its effects on bone metabolism. Androgen receptors are expressed in osteoblasts and osteoclasts, and AR agonism can influence both bone formation and resorption. Research models suggest RAD-140 may increase bone mineral density through anabolic effects on osteoblast activity.

RAD-140 vs. Other SARMs: Research Comparison

Understanding how RAD-140 compares to other research compounds helps contextualize its potency and applications:

RAD-140 vs. LGD-4033

Both RAD-140 and LGD-4033 are considered high-potency SARMs, but they differ in key ways:

  • Potency: RAD-140 generally shows higher binding affinity and anabolic output in muscle tissue models
  • Half-life: LGD-4033 has a longer half-life in most animal models, which influences research protocol design
  • Research scope: RAD-140 has the additional neuroprotection research angle, while LGD-4033 is more extensively studied in bone density research
  • Selectivity: Both demonstrate strong muscle:prostate selectivity, but RAD-140’s anabolic-to-androgenic ratio tends to measure higher in comparative assays

For full details on the other side of this comparison, see the LGD-4033 research guide.

RAD-140 vs. MK-677

These compounds operate through entirely different mechanisms:

  • RAD-140: Direct androgen receptor agonist — anabolic effects through AR binding in muscle and bone
  • MK-677: Ghrelin receptor agonist — anabolic effects mediated through GH/IGF-1 axis

RAD-140 produces more direct and potent anabolic signaling in muscle tissue. MK-677 offers a different pathway that doesn’t involve androgen receptors. For researchers studying multiple anabolic pathways, both compounds can be relevant — but they should not be conflated as interchangeable. See the MK-677 research guide for full details.

RAD-140 vs. MK-2866 (Ostarine)

  • RAD-140: Significantly more potent in muscle tissue models, higher binding affinity
  • MK-2866: Milder, more extensively studied in clinical settings, higher published safety data
  • Selectivity: MK-2866 is highly selective but less anabolically potent per unit concentration

Quick Comparison Summary:

  • RAD-140: Highest anabolic potency, AR agonist, neuroprotection research. Shop RAD-140
  • LGD-4033: High anabolic potency, long half-life, bone density focus.
  • MK-677: GHSR agonist, GH/IGF-1 pathway, metabolic research.
  • MK-2866: Mild anabolic, high selectivity, most clinical data.

Frequently Asked Questions About RAD-140 Research

What is RAD-140 used for in research?

RAD-140 is researched for its effects on skeletal muscle tissue, neuroprotection, bone density, and breast cancer cell models. As a selective androgen receptor modulator, it produces strong anabolic signaling in muscle and bone while minimizing androgenic effects in other tissues. All RAD-140 sold by BioPharma is for in vitro research purposes only and not for human consumption.

Is RAD-140 the most potent SARM for research?

Based on published receptor binding data and in vitro anabolic assays, RAD-140 is consistently among the most potent SARMs studied. Its binding affinity and anabolic-to-androgenic ratio measure higher than most other SARMs in comparative models. However, “most potent” depends on the specific endpoint and tissue type being studied.

How does RAD-140 differ from testosterone in research?

Both RAD-140 and testosterone activate the androgen receptor, but RAD-140 is tissue-selective while testosterone is not. Testosterone activates AR across all tissues — muscle, prostate, skin, liver, etc. — and also aromatizes to estrogen and undergoes 5-alpha reduction to DHT. RAD-140 avoids aromatization and 5-alpha reduction, and its tissue-selective co-regulator recruitment means it produces anabolic effects in muscle with minimal androgenic activity in the prostate and other non-target tissues.

Can RAD-140 be researched alongside other SARMs?

Some research protocols do examine RAD-140 in combination with other SARMs or with growth hormone secretagogues like MK-677. However, combining compounds introduces additional variables — different half-lives, binding affinities, and dose-response curves — that require careful experimental design. Each compound should be thoroughly characterized individually before combined research is considered.

Where can I buy RAD-140 for research in Canada?

BioPharma sells high-purity RAD-140 (testolone) for in vitro research purposes. Every batch is third-party tested for purity and identity. Purchase RAD-140 here. All products are sold strictly for research use — not for human consumption.

Does RAD-140 aromatize like testosterone?

No. RAD-140 does not aromatize to estrogen and does not undergo 5-alpha reduction to DHT. This is one of the key pharmacological differences between RAD-140 and testosterone in research models. The absence of aromatization means RAD-140 does not produce estrogenic effects in vitro, and the absence of 5-alpha reduction eliminates the DHT pathway.

Related Research Guides

Explore the broader SARMs research ecosystem:

  • SARMs Research Guide — Complete overview of selective androgen receptor modulators, categories, and research directions
  • MK-677 Research Guide — Deep dive into ibutamoren’s ghrelin receptor agonism and GH/IGF-1 pathway
  • LGD-4033 Research Guide — Explore ligandrol’s anabolic profile and bone density research applications

Shop RAD-140 Research Compound

Source high-purity testolone for your research protocols:

  • RAD-140 (Testolone) — High-potency SARM for muscle tissue, neuroprotection, and anabolic signaling research

All compounds discussed on this page are sold by BioPharma for in vitro research purposes only. They are not intended for human or veterinary use. This content is provided for informational purposes and does not constitute medical advice. RAD-140 has not been approved by Health Canada or the FDA for human consumption.